Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Costanza Maria Cristiani, Alice Turdo, Valeria Ventura, Tiziana Apuzzo, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Cinzia Garofalo, Emilia Dora Giovannone, Antonio M Grimaldi, Rossana Tallerico, Emanuela Marcenaro, Silvia Pesce, Genny Del Zotto, Valter Agosti, Francesco Saverio Costanzo, Elio Gulletta, Aroldo Rizzo, Alessandro Moretta, Klas Karre & 3 others Paolo A Ascierto, Matilde Todaro, Ennio Carbone

Research output: Contribution to journalArticle

Abstract

Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T-cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T-cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7+CD56bright NK cells as well as high serum concentrations of the CCR7 ligand CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The CCR7+ melanoma cell subpopulation coexpressed PD-L1 and Galectin-9 and had stemness properties. Analysis of melanoma-derived cancer stem cells (CSC) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of CCR7+, PD-L1+, and Galectin-9+ melanoma cells in melanoma metastases was demonstrated ex vivo Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma pathway.

Original languageEnglish
Pages (from-to)841-852
Number of pages12
JournalCancer immunology research
Volume7
Issue number5
DOIs
Publication statusPublished - May 2019

Fingerprint

Natural Killer Cells
Melanoma
Galectins
Neoplastic Stem Cells
T-Lymphocyte Subsets
Serum
Disease Progression
Blood Cells
Biomarkers
Cytokines
Neoplasm Metastasis
Ligands
T-Lymphocytes
Cell Line

Cite this

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. / Cristiani, Costanza Maria; Turdo, Alice; Ventura, Valeria; Apuzzo, Tiziana; Capone, Mariaelena; Madonna, Gabriele; Mallardo, Domenico; Garofalo, Cinzia; Giovannone, Emilia Dora; Grimaldi, Antonio M; Tallerico, Rossana; Marcenaro, Emanuela; Pesce, Silvia; Zotto, Genny Del; Agosti, Valter; Costanzo, Francesco Saverio; Gulletta, Elio; Rizzo, Aroldo; Moretta, Alessandro; Karre, Klas; Ascierto, Paolo A; Todaro, Matilde; Carbone, Ennio.

In: Cancer immunology research, Vol. 7, No. 5, 05.2019, p. 841-852.

Research output: Contribution to journalArticle

Cristiani, CM, Turdo, A, Ventura, V, Apuzzo, T, Capone, M, Madonna, G, Mallardo, D, Garofalo, C, Giovannone, ED, Grimaldi, AM, Tallerico, R, Marcenaro, E, Pesce, S, Zotto, GD, Agosti, V, Costanzo, FS, Gulletta, E, Rizzo, A, Moretta, A, Karre, K, Ascierto, PA, Todaro, M & Carbone, E 2019, 'Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway', Cancer immunology research, vol. 7, no. 5, pp. 841-852. https://doi.org/10.1158/2326-6066.CIR-18-0651
Cristiani, Costanza Maria ; Turdo, Alice ; Ventura, Valeria ; Apuzzo, Tiziana ; Capone, Mariaelena ; Madonna, Gabriele ; Mallardo, Domenico ; Garofalo, Cinzia ; Giovannone, Emilia Dora ; Grimaldi, Antonio M ; Tallerico, Rossana ; Marcenaro, Emanuela ; Pesce, Silvia ; Zotto, Genny Del ; Agosti, Valter ; Costanzo, Francesco Saverio ; Gulletta, Elio ; Rizzo, Aroldo ; Moretta, Alessandro ; Karre, Klas ; Ascierto, Paolo A ; Todaro, Matilde ; Carbone, Ennio. / Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. In: Cancer immunology research. 2019 ; Vol. 7, No. 5. pp. 841-852.
@article{b8910a8a447042c397dc9a6f9c0e9e43,
title = "Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway",
abstract = "Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T-cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T-cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7+CD56bright NK cells as well as high serum concentrations of the CCR7 ligand CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The CCR7+ melanoma cell subpopulation coexpressed PD-L1 and Galectin-9 and had stemness properties. Analysis of melanoma-derived cancer stem cells (CSC) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of CCR7+, PD-L1+, and Galectin-9+ melanoma cells in melanoma metastases was demonstrated ex vivo Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma pathway.",
author = "Cristiani, {Costanza Maria} and Alice Turdo and Valeria Ventura and Tiziana Apuzzo and Mariaelena Capone and Gabriele Madonna and Domenico Mallardo and Cinzia Garofalo and Giovannone, {Emilia Dora} and Grimaldi, {Antonio M} and Rossana Tallerico and Emanuela Marcenaro and Silvia Pesce and Zotto, {Genny Del} and Valter Agosti and Costanzo, {Francesco Saverio} and Elio Gulletta and Aroldo Rizzo and Alessandro Moretta and Klas Karre and Ascierto, {Paolo A} and Matilde Todaro and Ennio Carbone",
note = "{\circledC}2019 American Association for Cancer Research.",
year = "2019",
month = "5",
doi = "10.1158/2326-6066.CIR-18-0651",
language = "English",
volume = "7",
pages = "841--852",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

AU - Cristiani, Costanza Maria

AU - Turdo, Alice

AU - Ventura, Valeria

AU - Apuzzo, Tiziana

AU - Capone, Mariaelena

AU - Madonna, Gabriele

AU - Mallardo, Domenico

AU - Garofalo, Cinzia

AU - Giovannone, Emilia Dora

AU - Grimaldi, Antonio M

AU - Tallerico, Rossana

AU - Marcenaro, Emanuela

AU - Pesce, Silvia

AU - Zotto, Genny Del

AU - Agosti, Valter

AU - Costanzo, Francesco Saverio

AU - Gulletta, Elio

AU - Rizzo, Aroldo

AU - Moretta, Alessandro

AU - Karre, Klas

AU - Ascierto, Paolo A

AU - Todaro, Matilde

AU - Carbone, Ennio

N1 - ©2019 American Association for Cancer Research.

PY - 2019/5

Y1 - 2019/5

N2 - Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T-cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T-cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7+CD56bright NK cells as well as high serum concentrations of the CCR7 ligand CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The CCR7+ melanoma cell subpopulation coexpressed PD-L1 and Galectin-9 and had stemness properties. Analysis of melanoma-derived cancer stem cells (CSC) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of CCR7+, PD-L1+, and Galectin-9+ melanoma cells in melanoma metastases was demonstrated ex vivo Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma pathway.

AB - Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T-cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T-cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7+CD56bright NK cells as well as high serum concentrations of the CCR7 ligand CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The CCR7+ melanoma cell subpopulation coexpressed PD-L1 and Galectin-9 and had stemness properties. Analysis of melanoma-derived cancer stem cells (CSC) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of CCR7+, PD-L1+, and Galectin-9+ melanoma cells in melanoma metastases was demonstrated ex vivo Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma pathway.

U2 - 10.1158/2326-6066.CIR-18-0651

DO - 10.1158/2326-6066.CIR-18-0651

M3 - Article

VL - 7

SP - 841

EP - 852

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 5

ER -